drugset / Trial / NCT04959266

A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib

NCT04959266

Phase 1 Terminated 5 enrolled AstraZeneca Parexel · collab
Non-randomizedCrossoverOpen-labelOther

Summary

This is a Phase 1, open-label, non-randomised, 3-arm (A, B, and C), drug-drug interaction study in patients with advanced solid tumours.

Timeline

Start
2021-06-28
Primary completion
2022-06-01
Completion
2022-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Adavosertib Small molecule Oral
Subject Itraconazole Small molecule Oral
Subject Omeprazole Other / unclassified Oral
Subject Rifampin Small molecule Oral

Indications